Goldman Sachs Downgrades Acadia Pharmaceuticals (ACAD) to Neutral, 'Looking for clarity on forward path from Type A meeting'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral with a price target of $25.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
